

30 July 2010

Proposal for radiological contrast media

PHARMAC is seeking feedback on a proposal to list in Part II of Section H of the Pharmaceutical Schedule, or amend the listing of, a number of radiological contrast media as part of a provisional agreement with Regional Health Limited. In summary, this proposal would result in:

- listing of CTPlus, a brand of barium sulphate oral suspension from 1 September 2010; and
- ongoing listings for Multihance and loscan, with a small price increase for loscan from 1 September 2010.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Thursday, 12 August 2010** to:

Andrew Davies	Email: andrew.davies@pharmac.govt.nz
Procurement Initiatives Manager	
PHARMAC	Fax: 04 460 4995
PO Box 10 254	
Wellington 6143	

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal

The following listings would be effective in Part II of Section H of the Pharmaceutical Schedule from 1 September 2010:

Chemical	Presentation	Brand	Pack size	Price
Gadobendate dimeglumine	Solution for injection, 0.5 g per L, 10 mL	MultiHance	10	\$324.74
Gadobendate dimeglumine	Solution for injection, 0.5 g per L, 20 mL	MultiHance	10	\$636.28
Sodium diatrizoate	Oral solution, 3.705 g per 10 mL sachet	loscan	50	\$156.12
Barium sulphate	Oral suspension, 2.2%, 250 mL bottle	CT Plus+	24	\$175.00
Barium sulphate	Oral suspension, 2.2%, 450 mL bottle	CT Plus+	24	\$220.00

None of the products would have Hospital Supply Status, but they would be protected from delisting until 30 June 2012, meaning no other supplier could gain Hospital Supply Status for these product categories in this time.